All News
Abatacept Safety Outcomes Across 7 European Registries
A multinational registry analysis of rheumatoid arthritis (RA) receiving abatacept (ABA) has shown that the safety profile of ABA remains unchanged with no new or increased risks of infection or malignancy.
Read Article
2023 EULAR Recommendations on Imaging in Crystal-Induced Arthritis
New recommendations on imaging for crystal-induced (gout, CPPD) arthritis (CiA) were presented at EULAR 2023 in Milan.
Read Article
Higher Genetic Loads Linked to Worse Systemic Lupus
A study of a large SLE cohort shows by genomic analysis, that higher wGRS is associated with earlier SLE onset, higher anti–Sm antibody positivity, lupus nephritis and more diverse lupus manifestations.
https://t.co/L8ZZEgcfNM https://t.co/elwDtDuSjP
Links:
Dr. John Cush RheumNow ( View Tweet)
WATCH: Update on CAR T-Cell Therapy in SLE & Autoimmune Diseases
Dr. Peter Nash reporting from EULAR 2023 in Milan, Italy.
https://t.co/EpsPtwtJJt https://t.co/QxH8Pff6RS
Links:
Dr. John Cush RheumNow ( View Tweet)
275 early RA pts and after 2 years, 32% reported unacceptable pain (UP). Predictors of UP best seen at 3 mos FUV (not baseline) and included #Tender Jts (not swollen), overall pain, patient global assessment, and HAQ. https://t.co/Zlv3919Ucz https://t.co/1K1zPvhUYi
Links:
Dr. John Cush RheumNow ( View Tweet)
EULAR Offers Tips on Psoriasis Progression to PsA
Clinicians treating patients with psoriasis should be on the lookout for certain signs that joint involvement is likely to develop, according to a new "points to consider" from the EULAR.
https://t.co/eFsWJBmzCR https://t.co/slq58tWJG6
Links:
Dr. John Cush RheumNow ( View Tweet)
Biosimilars Match Biologic Originators in RA
A JAMA review shows that biosimilars of adalimumab, infliximab, and etanercept were associated w/clinically equivalent treatment effects compared with their ref biologics for treatment of RA.
https://t.co/EO22ThFL5C https://t.co/wlK0e2Cg5l
Links:
Dr. John Cush RheumNow ( View Tweet)
BIOSIMILARS (93 in EU, 40 in US) are approaching a tipping point with 8 new adalimumab biosimilars in 2023. Humira sales are down ~26% in 2023. Biosimilar sales expected - $129 billion in next 5 yrs, with estimated savings of $181 billion https://t.co/HMOYaSaIBQ https://t.co/6jOujr4JXQ
Links:
Dr. John Cush RheumNow ( View Tweet)
Time to Risk Stratify Methotrexate Lab Monitoring?
A longitudinal cohort analysis has developed a prognostic model that informs a risk stratified approach to monitoring blood tests during long term methotrexate (MTX) therapy.
https://t.co/AP89MAIlJM https://t.co/YpfWFCLF1z
Links:
Dr. John Cush RheumNow ( View Tweet)
Should we be reassured of JAK safety with new data?
Dr. Janet Pope discusses abstracts OP0133 and OP0132 at EULAR 2023 in Milan, Italy.
https://t.co/gxLJGHXwlm https://t.co/SgdGRJXBIi
Links:
Dr. John Cush RheumNow ( View Tweet)
Bimekizumab (Bimzelx) has been EMA approved to treat adults with active PsA & axial spondylarthritis in the EU. This dual IL-17 A/F inhibitor is approved to treat moderate -severe plaque psoriasis in the EU, Canada, UK & Japan; but not yet in USA https://t.co/DGczkgHtpZ https://t.co/TquFCuh4QG
Links:
Dr. John Cush RheumNow ( View Tweet)
Swedish registry study shows of 3629 children born to mothers with RA#, 70 (1.94%) were diagnosed with Autism Spectrum disorder (ASD). If RA was dx before delivery, an increased risk of ASD (HR = 1.43), especially for seronegative RA (HR = 1.61) https://t.co/fA6gzta5rx https://t.co/mGdzTqjEr7
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s newly launched Poster Hall features sponsor-generated clinical trial posters designed to educate and inform. Check out our Poster Hall today!
https://t.co/opulSMICUf https://t.co/XtWePsWQCt
Links:
Dr. John Cush RheumNow ( View Tweet)
Assessment of Psoriatic Arthritis: A Global Perspective
Drs. Antoni Chan, Nelly Ziade and Ihsane Hmamouchi discuss POS1542 presented at EULAR 2023 in Milan, Italy.
https://t.co/qkhdNDn37k https://t.co/Ux4PCxRdn8
Links:
Dr. John Cush RheumNow ( View Tweet)
Dazodalibep: A Glimmer of Hope is Sjogren's Syndrome?
Dr. Yuz Yusof reports on abstracts OP0143 and LB0003 presented at EULAR 2023 in Milan, Italy.
https://t.co/TPcdJ2rIsP https://t.co/5WZizA0TU8
Links:
Dr. John Cush RheumNow ( View Tweet)
What to do with all this JAKi safety real world data?
Dr. David Liew reporting from EULAR 2023 in Milan, Italy.
https://t.co/AgDBOxAUx6 https://t.co/iRZuT0g7vq
Links:
Dr. John Cush RheumNow ( View Tweet)
Why Depression Screening Should be Mandatory at Each Visit
Depression is more widespread than ever in the US, according to a new study from Gallup, showing that 18% of adults are depressed– an increase in 7 percentage points since 2015.
https://t.co/2u82MXIFvb https://t.co/ZpGi4TYdBL
Links:
Dr. John Cush RheumNow ( View Tweet)
High Mortality Rates with Depression in Rheumatoid Arthritis
A Danish cohort study has shown a deadly association between depression and rheumatoid arthritis (RA).
https://t.co/R2MB4bs0Hr https://t.co/rWIfHmBqr8
Links:
Dr. John Cush RheumNow ( View Tweet)
Excessive alcohol intake associated with higher risks of 61 diseases in men, including liver cirrhosis, stroke, and several gastrointestinal cancers, gout, cataracts, some fractures, and gastric ulcer. https://t.co/WqMuHQ3Unn https://t.co/IU0SaRcswZ
Dr. John Cush RheumNow ( View Tweet)
519 pts in the Hand OSTeoArthritis in Secondary care (HOSTAS) cohort studied & 17% had prolonged morning stiffness (>60 min); mild in 30%, intermediate in 37%, severe in 18% and extreme in 4%. Assoc w/ more pain, worse function and QOL https://t.co/6LSir7nSae https://t.co/lhoxwpfuqD
Links:
Dr. John Cush RheumNow ( View Tweet)